DiaMedica Therapeutics (NASDAQ:DMAC) is a clinical-stage biopharmaceutical company developing novel recombinant proteins for renal and neurological diseases. The company comprises a team of seasoned biopharma professionals and financial experts who are moving the company’s proprietary products through clinical trials and to commercialization.